

# Hongliang Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5014278/publications.pdf>

Version: 2024-02-01

181  
papers

12,557  
citations

34105

52  
h-index

30087

103  
g-index

185  
all docs

185  
docs citations

185  
times ranked

18772  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcutaneous vagus nerve stimulation attenuates autoantibody-mediated cardiovagal dysfunction and inflammation in a rabbit model of postural tachycardia syndrome. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2023, 66, 291-300.	1.3	7
2	A conventional immune regulator mitochondrial antiviral signaling protein blocks hepatic steatosis by maintaining mitochondrial homeostasis. <i>Hepatology</i> , 2022, 75, 403-418.	7.3	15
3	Implications of Antimuscarinic Autoantibodies in Postural Tachycardia Syndrome. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 438-440.	2.4	6
4	Melanoma differentiation-associated gene 5 protects against NASH in mice. <i>Hepatology</i> , 2022, 75, 924-938.	7.3	8
5	N-acetylgalactosaminyltransferase 4 protects against hepatic ischemia/reperfusion injury by blocking apoptosis signal-regulating kinase 1 terminal dimerization. <i>Hepatology</i> , 2022, 75, 1446-1460.	7.3	18
6	NAFLD as a continuous driver in the whole spectrum of vascular disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 163, 118-132.	1.9	17
7	Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities. <i>Journal of Infection and Public Health</i> , 2022, 15, 13-20.	4.1	30
8	Targeting ACC for NASH resolution. <i>Trends in Molecular Medicine</i> , 2022, 28, 5-7.	6.7	9
9	High Remnant Cholesterol Level Potentiates the Development of Hypertension. <i>Frontiers in Endocrinology</i> , 2022, 13, 830347.	3.5	20
10	Projection of global burden and risk factors for aortic aneurysm – timely warning for greater emphasis on managing blood pressure. <i>Annals of Medicine</i> , 2022, 54, 553-564.	3.8	16
11	A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2022, 13, 821689.	3.5	12
12	Global death burden and attributable risk factors of peripheral artery disease by age, sex, SDI regions, and countries from 1990 to 2030: Results from the Global Burden of Disease study 2019. <i>Atherosclerosis</i> , 2022, 347, 17-27.	0.8	7
13	Distributions and trends of the global burden of COPD attributable to risk factors by SDI, age, and sex from 1990 to 2019: a systematic analysis of GBD 2019 data. <i>Respiratory Research</i> , 2022, 23, 90.	3.6	33
14	The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy. <i>Circulation Research</i> , 2022, 130, 1586-1600.	4.5	21
15	Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C630-C639.	4.6	10
16	Milk Fat Globule – Epidermal Growth Factor – Factor 8 Improves Hepatic Steatosis and Inflammation. <i>Hepatology</i> , 2021, 73, 586-605.	7.3	27
17	Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta – Activated Kinase 1 – c-Jun – Terminal Kinase/p38 Signaling. <i>Hepatology</i> , 2021, 73, 104-125.	7.3	40
18	Kidney Function Indicators Predict Adverse Outcomes of COVID-19. <i>Med</i> , 2021, 2, 38-48.e2.	4.4	47

#	ARTICLE	IF	CITATIONS
19	The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. <i>Cell Metabolism</i> , 2021, 33, 258-269.e3.	16.2	87
20	M 2 muscarinic autoantibodies and thyroid hormone promote susceptibility to atrial fibrillation and sinus tachycardia in an autoimmune rabbit model. <i>Experimental Physiology</i> , 2021, 106, 882-890.	2.0	3
21	Gonadotrophin-releasing hormone receptor autoantibodies induce polycystic ovary syndrome-like features in a rat model. <i>Experimental Physiology</i> , 2021, 106, 902-912.	2.0	5
22	Ganglionated Plexi Ablation Suppresses Chronic Obstructive Sleep Apnea-Related Atrial Fibrillation by Inhibiting Cardiac Autonomic Hyperactivation. <i>Frontiers in Physiology</i> , 2021, 12, 640295.	2.8	6
23	A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. <i>Current Medical Research and Opinion</i> , 2021, 37, 917-927.	1.9	11
24	Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. <i>Circulation Research</i> , 2021, 128, 1747-1765.	4.5	49
25	Increased testosterone and proinflammatory cytokines in patients with polycystic ovary syndrome correlate with elevated GnRH receptor autoantibody activity assessed by a fluorescence resonance energy transfer-based bioassay. <i>Endocrine</i> , 2021, 74, 163-171.	2.3	5
26	A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis. <i>Cell Metabolism</i> , 2021, 33, 1171-1186.e9.	16.2	10
27	TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease. <i>Cell Metabolism</i> , 2021, 33, 1640-1654.e8.	16.2	22
28	Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD. <i>Hepatology</i> , 2021, 74, 1319-1338.	7.3	11
29	TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury. <i>Hepatology</i> , 2021, 74, 2133-2153.	7.3	20
30	Therapeutic Potential of G Protein-Coupled Receptors Against Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2021, 74, 2831-2838.	7.3	10
31	Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. <i>Cell Metabolism</i> , 2021, 33, 2059-2075.e10.	16.2	35
32	Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD. <i>Hepatology</i> , 2021, 74, 2508-2525.	7.3	44
33	Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications. <i>Hepatology</i> , 2021, 74, 2839-2847.	7.3	35
34	Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. <i>Cell Metabolism</i> , 2021, 33, 1943-1956.e2.	16.2	59
35	Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. <i>Frontiers in Medicine</i> , 2021, 8, 761538.	2.6	25
36	Autoimmune activation of the GnRH receptor induces insulin resistance independent of obesity in a female rat model. <i>Physiological Reports</i> , 2021, 8, e14672.	1.7	2

#	ARTICLE	IF	CITATIONS
37	GnRH receptor-activating autoantibodies in polycystic ovary syndrome: identification of functional epitopes and development of epitope mimetic inhibitors. <i>Endocrine</i> , 2021, , 1.	2.3	2
38	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. <i>Science Translational Medicine</i> , 2021, 13, eabg8116.	12.4	30
39	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2021, 13, eabg8117.	12.4	23
40	Heavy Disease Burden of High Systolic Blood Pressure During 1990-2019: Highlighting Regional, Sex, and Age Specific Strategies in Blood Pressure Control. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 754778.	2.4	14
41	Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1. <i>Hepatology</i> , 2020, 71, 93-111.	7.3	55
42	Nonalcoholic Fatty Liver Disease. <i>Hypertension</i> , 2020, 75, 275-284.	2.7	121
43	Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. <i>Cell Metabolism</i> , 2020, 32, 537-547.e3.	16.2	116
44	Ca <sup>2+</sup> -Dependent NOX5 (NADPH Oxidase 5) Exaggerates Cardiac Hypertrophy Through Reactive Oxygen Species Production. <i>Hypertension</i> , 2020, 76, 827-838.	2.7	42
45	The Role of GnRH Receptor Autoantibodies in Polycystic Ovary Syndrome. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa078.	0.2	10
46	SUN-LB5 GnRHR ECL-2 Epitopes Targeted by Activating Autoantibodies in Polycystic Ovary Syndrome. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	1
47	Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 892-908.e11.	16.2	92
48	MON-002 The Effect of GNRHR Autoantibody on Reproduction Function and Insulin Signaling Intermediates in a New Animal Model of Polycystic Ovary Syndrome. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	1
49	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. <i>Cell Metabolism</i> , 2020, 32, 176-187.e4.	16.2	400
50	Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19." <i>Circulation Research</i> , 2020, 126, e142-e143.	4.5	79
51	Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 412-414.	3.0	51
52	Activation of $\alpha 7$ nAChR via vagus nerve prevents obesity-induced insulin resistance via suppressing endoplasmic reticulum stress-induced inflammation in Kupffer cells. <i>Medical Hypotheses</i> , 2020, 140, 109671.	1.5	8
53	Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. <i>Free Radical Biology and Medicine</i> , 2020, 152, 116-141.	2.9	574
54	Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. <i>Hepatology</i> , 2020, 72, 1491-1493.	7.3	102

#	ARTICLE	IF	CITATIONS
55	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. <i>Circulation Research</i> , 2020, 126, 679-704.	4.5	121
56	Epidemiological Features of NAFLD From 1999 to 2018 in China. <i>Hepatology</i> , 2020, 71, 1851-1864.	7.3	341
57	Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. <i>Hepatology</i> , 2020, 72, 389-398.	7.3	346
58	Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. <i>Cell Metabolism</i> , 2020, 31, 1068-1077.e3.	16.2	1,207
59	TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation. <i>Cell Metabolism</i> , 2020, 31, 726-740.e8.	16.2	60
60	Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. <i>Circulation Research</i> , 2020, 126, 1671-1681.	4.5	948
61	The Science Underlying COVID-19. <i>Circulation</i> , 2020, 142, 68-78.	1.6	682
62	Leukocyte immunoglobulin-like receptor B4 protects against cardiac hypertrophy via SHP-2-dependent inhibition of the NF- $\kappa$ B pathway. <i>Journal of Molecular Medicine</i> , 2020, 98, 691-705.	3.9	11
63	ACE2 the Janus-faced protein “ from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. <i>Clinical Science</i> , 2020, 134, 747-750.	4.3	57
64	Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. <i>Clinical Science</i> , 2020, 134, 1775-1799.	4.3	25
65	High cytoplasmic YAP1 expression predicts a poor prognosis in patients with colorectal cancer. <i>PeerJ</i> , 2020, 8, e10397.	2.0	6
66	Sophoricoside ameliorates cardiac hypertrophy by activating AMPK/mTORC1-mediated autophagy. <i>Bioscience Reports</i> , 2020, 40, .	2.4	7
67	Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. <i>Medicinal Research Reviews</i> , 2019, 39, 328-348.	10.5	105
68	Reply:. <i>Hepatology</i> , 2019, 70, 2239-2240.	7.3	0
69	Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. <i>Gene Expression</i> , 2019, 19, 187-198.	1.2	23
70	Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 903-914.	7.1	85
71	F-box/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice. <i>Hepatology</i> , 2019, 70, 1942-1957.	7.3	36
72	A functional cell-based bioassay for assessing adrenergic autoantibody activity in postural tachycardia syndrome. <i>Journal of Translational Autoimmunity</i> , 2019, 2, 100006.	4.0	7

#	ARTICLE	IF	CITATIONS
73	Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2019, 70, 1119-1133.	7.3	355
74	Integrated Omics Reveals Tollip as an Regulator and Therapeutic Target for Hepatic Ischemia-Perfusion Injury in Mice. <i>Hepatology</i> , 2019, 70, 1750-1769.	7.3	44
75	Innate immune regulatory networks in hepatic lipid metabolism. <i>Journal of Molecular Medicine</i> , 2019, 97, 593-604.	3.9	57
76	A novel RIT1 mutation causes deterioration of Noonan syndrome-associated cardiac hypertrophy. <i>EBioMedicine</i> , 2019, 42, 6-7.	6.1	1
77	Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor $\beta$ in Mice. <i>Hepatology</i> , 2019, 69, 2471-2488.	7.3	37
78	Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. <i>Gene Expression</i> , 2019, 19, 175-185.	1.2	20
79	Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 153-184.	22.4	65
80	Innate Immune Signaling and Its Role in Metabolic and Cardiovascular Diseases. <i>Physiological Reviews</i> , 2019, 99, 893-948.	28.8	57
81	The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 70, 1026-1037.	7.3	146
82	Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid monotherapy. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 165-171.	2.2	12
83	A Maitake ( <i>Grifola frondosa</i> ) polysaccharide ameliorates Alzheimer's disease-like pathology and cognitive impairments by enhancing microglial amyloid- $\beta$ clearance. <i>RSC Advances</i> , 2019, 9, 37127-37135.	3.6	25
84	A Polysaccharide Extract from Maitake Culinary-Medicinal Mushroom, <i>Grifola frondosa</i> (Agaricomycetes) Ameliorates Learning and Memory Function in Aluminum Chloride-Induced Amnesia in Mice. <i>International Journal of Medicinal Mushrooms</i> , 2019, 21, 1065-1074.	1.5	7
85	Angiotensin II Type 1 Receptor Autoantibodies in Postural Tachycardia Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	67
86	Time to step up the fight against NAFLD. <i>Hepatology</i> , 2018, 67, 2068-2071.	7.3	29
87	Long non-coding RNA PVT1-5 promotes cell proliferation by regulating miR-126/SLC7A5 axis in lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 2350-2355.	2.1	64
88	Dusp14 protects against hepatic ischaemia-perfusion injury via Tak1 suppression. <i>Journal of Hepatology</i> , 2018, 68, 118-129.	3.7	50
89	An ALOX12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-perfusion injury. <i>Nature Medicine</i> , 2018, 24, 73-83.	30.7	155
90	The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. <i>Nature Medicine</i> , 2018, 24, 84-94.	30.7	145

#	ARTICLE	IF	CITATIONS
91	Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy. <i>Circulation</i> , 2018, 137, 1486-1504.	1.6	32
92	Long non-coding RNA 1308 promotes cell invasion by regulating the miR-124/ADAM 15 axis in non-small-cell lung cancer cells. <i>Cancer Management and Research</i> , 2018, Volume 10, 6599-6609.	1.9	25
93	Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1. <i>Journal of Hepatology</i> , 2018, 69, 1110-1122.	3.7	46
94	Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 712-722.	7.1	66
95	Wang et al. reply. <i>Nature Medicine</i> , 2018, 24, 700-701.	30.7	3
96	Tollip Negatively Regulates Vascular Smooth Muscle Cell-Mediated Neointima Formation by Suppressing Akt-Dependent Signaling. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	10
97	The innate immune signaling in cancer and cardiometabolic diseases: Friends or foes?. <i>Cancer Letters</i> , 2017, 387, 46-60.	7.2	17
98	Ablation of Interferon Regulatory Factor 3 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice. <i>Hypertension</i> , 2017, 69, 510-520.	2.7	24
99	Dickkopf-3 Ablation Attenuates the Development of Atherosclerosis in ApoE-Deficient Mice. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	28
100	Vinexin Î² Ablation Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice by Inactivating the Akt-Nuclear Factor Î²B Inflammatory Axis. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	13
101	Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. <i>Nature Medicine</i> , 2017, 23, 439-449.	30.7	183
102	Oncostatin M receptor Î² deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages. <i>Journal of Lipid Research</i> , 2017, 58, 895-906.	4.2	53
103	Reprogramming Interferon Regulatory Factor Signaling in Cardiometabolic Diseases. <i>Physiology</i> , 2017, 32, 210-223.	3.1	24
104	Reprogramming Innate Immune Signaling in Cardiometabolic Disease. <i>Hypertension</i> , 2017, 69, 747-760.	2.7	23
105	The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis. <i>Hepatology</i> , 2017, 65, 1492-1511.	7.3	70
106	<i>Grifflola frondosa</i> (GF) produces significant antidepressant effects involving AMPA receptor activation in mice. <i>Pharmaceutical Biology</i> , 2017, 55, 299-305.	2.9	2
107	Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor Î²-Activated Kinase Î³-Dependent Signaling Pathways. <i>Hypertension</i> , 2017, 69, 249-258.	2.7	43
108	Interferon Regulatory Factor 4 Inhibits Neointima Formation by Engaging KrÄ¼ppel-Like Factor 4 Signaling. <i>Circulation</i> , 2017, 136, 1412-1433.	1.6	33

#	ARTICLE	IF	CITATIONS
109	Restoration of Circulating MFGE8 (Milk Fat Globule-EGF Factor 8) Attenuates Cardiac Hypertrophy Through Inhibition of Akt Pathway. <i>Hypertension</i> , 2017, 70, 770-779.	2.7	37
110	Control of Pathological Cardiac Hypertrophy by Transcriptional Corepressor IRF2BP2 (Interferon) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 7	2.7	16
111	Insights into innate immune signalling in controlling cardiac remodelling. <i>Cardiovascular Research</i> , 2017, 113, 1538-1550.	3.8	46
112	Antiadrenergic autoimmunity in postural tachycardia syndrome. <i>Europace</i> , 2017, 19, 1211-1219.	1.7	110
113	Targeting Interferon Regulatory Factor for Cardiometabolic Diseases: Opportunities and Challenges. <i>Current Drug Targets</i> , 2017, 18, 1754-1778.	2.1	16
114	Attenuation of cerebral ischemic injury in interferon regulatory factor 3-deficient rat. <i>Journal of Neurochemistry</i> , 2016, 136, 871-883.	3.9	16
115	Liver capsule: IRFs in hepatocytes: Pathophysiology. <i>Hepatology</i> , 2016, 63, 1706-1706.	7.3	12
116	Loss of Caspase-Activated DNase Protects Against Atherosclerosis in Apolipoprotein E-deficient Mice. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	7
117	Cardiac-Specific EPI64C Blunts Pressure Overload-Induced Cardiac Hypertrophy. <i>Hypertension</i> , 2016, 67, 866-877.	2.7	16
118	Hepatic Oncostatin M Receptor $\beta$ 2 Regulates Obesity-Induced Steatosis and Insulin Resistance. <i>American Journal of Pathology</i> , 2016, 186, 1278-1292.	3.8	30
119	Mnk1 (Mitogen-Activated Protein Kinase-Interacting Kinase 1) Deficiency Aggravates Cardiac Remodeling in Mice. <i>Hypertension</i> , 2016, 68, 1393-1399.	2.7	30
120	Cisapride, a selective serotonin 5-HT <sub>4</sub> -receptor agonist, inhibits voltage-dependent K <sup>+</sup> channels in rabbit coronary arterial smooth muscle cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 478, 1423-1428.	2.1	4
121	The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. <i>Nature Medicine</i> , 2016, 22, 1131-1139.	30.7	331
122	Type III Transforming Growth Factor- $\beta$ 2 Receptor Drives Cardiac Hypertrophy Through $\beta$ 2-Arrestin2-Dependent Activation of Calmodulin-Dependent Protein Kinase II. <i>Hypertension</i> , 2016, 68, 654-666.	2.7	14
123	$\beta$ 1-Adrenergic and M2 Muscarinic Autoantibodies and Thyroid Hormone Facilitate Induction of Atrial Fibrillation in Male Rabbits. <i>Endocrinology</i> , 2016, 157, 16-22.	2.8	13
124	Suppressor of IKK $\epsilon$ is an essential negative regulator of pathological cardiac hypertrophy. <i>Nature Communications</i> , 2016, 7, 11432.	12.8	60
125	The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling. <i>Nature Communications</i> , 2016, 7, 11267.	12.8	143
126	Pivotal Role of Regulator of G-protein Signaling 12 in Pathological Cardiac Hypertrophy. <i>Hypertension</i> , 2016, 67, 1228-1236.	2.7	21



#	ARTICLE	IF	CITATIONS
127	Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. <i>Gastroenterology</i> , 2016, 151, 733-746.e12.	1.3	235
128	DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity. <i>Journal of Hepatology</i> , 2016, 65, 113-124.	3.7	55
129	Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis. <i>Journal of Hepatology</i> , 2016, 65, 125-136.	3.7	41
130	Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling. <i>Nature Communications</i> , 2016, 7, 10592.	12.8	95
131	Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. <i>Journal of Hepatology</i> , 2016, 64, 1365-1377.	3.7	113
132	Activation of integrin $\beta$ 5 mediated by flow requires its translocation to membrane lipid rafts in vascular endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 769-774.	7.1	85
133	Regulator of G-Protein Signaling 10 Negatively Regulates Cardiac Remodeling by Blocking Mitogen-Activated Protein Kinase-Extracellular Signal-Regulated Protein Kinase 1/2 Signaling. <i>Hypertension</i> , 2016, 67, 86-98.	2.7	42
134	Targeting TRAF3 signaling protects against hepatic ischemia/reperfusion injury. <i>Journal of Hepatology</i> , 2016, 64, 146-159.	3.7	79
135	Mindin regulates vascular smooth muscle cell phenotype and prevents neointima formation. <i>Clinical Science</i> , 2015, 129, 129-145.	4.3	47
136	Tollip is a critical mediator of cerebral ischaemia-reperfusion injury. <i>Journal of Pathology</i> , 2015, 237, 249-262.	4.5	25
137	Vinexin <sup>2</sup> deficiency protects against cerebral ischaemia/reperfusion injury by inhibiting neuronal apoptosis. <i>Journal of Neurochemistry</i> , 2015, 134, 211-221.	3.9	6
138	Toll-interacting protein contributes to mortality following myocardial infarction through promoting inflammation and apoptosis. <i>British Journal of Pharmacology</i> , 2015, 172, 3383-3396.	5.4	19
139	The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases. <i>British Journal of Pharmacology</i> , 2015, 172, 5457-5476.	5.4	34
140	Tumor Necrosis Factor Receptor-Associated Factor 3 Is a Positive Regulator of Pathological Cardiac Hypertrophy. <i>Hypertension</i> , 2015, 66, 356-367.	2.7	48
141	A peptidomimetic inhibitor suppresses the inducibility of $\beta$ 1-adrenergic autoantibody-mediated cardiac arrhythmias in the rabbit. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 44, 205-212.	1.3	12
142	Novel Role for Caspase-Activated DNase in the Regulation of Pathological Cardiac Hypertrophy. <i>Hypertension</i> , 2015, 65, 871-881.	2.7	30
143	Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF- $\beta$ /ASK1/JNK pathway. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 308, H1143-H1154.	3.2	71
144	Neuron-Specific Tumor Necrosis Factor Receptor-Associated Factor 3 Is a Central Regulator of Neuronal Death in Acute Ischemic Stroke. <i>Hypertension</i> , 2015, 66, 604-616.	2.7	33

#	ARTICLE	IF	CITATIONS
145	Interferon Regulatory Factor Signalings in Cardiometabolic Diseases. <i>Hypertension</i> , 2015, 66, 222-247.	2.7	43
146	Mindin deficiency protects the liver against ischemia/reperfusion injury. <i>Journal of Hepatology</i> , 2015, 63, 1198-1211.	3.7	34
147	Exacerbating Pressure Overloadâ€œInduced Cardiac Hypertrophy. <i>Hypertension</i> , 2015, 66, 571-581.	2.7	24
148	Cardioprotective role of growth/differentiation factor 1 in postâ€œinfarction left ventricular remodelling and dysfunction. <i>Journal of Pathology</i> , 2015, 236, 360-372.	4.5	14
149	Activating autoantibodies to the Î²1/2-adrenergic and M2 muscarinic receptors associate with atrial tachyarrhythmias in patients with hyperthyroidism. <i>Endocrine</i> , 2015, 49, 457-463.	2.3	18
150	AMPK Suppresses Vascular Inflammation In Vivo by Inhibiting Signal Transducer and Activator of Transcription-1. <i>Diabetes</i> , 2015, 64, 4285-4297.	0.6	58
151	Vinexin-Î² exacerbates cardiac dysfunction post-myocardial infarction via mediating apoptotic and inflammatory responses. <i>Clinical Science</i> , 2015, 128, 923-936.	4.3	8
152	Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv021-pyv021.	2.1	23
153	Regulatory role of CARD3 in left ventricular remodelling and dysfunction after myocardial infarction. <i>Basic Research in Cardiology</i> , 2015, 110, 56.	5.9	23
154	Oncostatin M Confers Neuroprotection against Ischemic Stroke. <i>Journal of Neuroscience</i> , 2015, 35, 12047-12062.	3.6	34
155	Reply to: â€œInterferon regulatory factor 9 plays a dual function in health and diseaseâ€œ. <i>Journal of Hepatology</i> , 2015, 62, 1447-1448.	3.7	1
156	Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury. <i>Journal of Hepatology</i> , 2015, 62, 111-120.	3.7	62
157	Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 365-378.	3.8	176
158	Regulator of G-protein signalling 5 protects against atherosclerosis in apolipoprotein E-deficient mice. <i>British Journal of Pharmacology</i> , 2015, 172, 5676-5689.	5.4	34
159	Interferon regulatory factor 9 is critical for neointima formation following vascular injury. <i>Nature Communications</i> , 2014, 5, 5160.	12.8	61
160	A Critical Role for Interferon Regulatory Factor 9 in Cerebral Ischemic Stroke. <i>Journal of Neuroscience</i> , 2014, 34, 11897-11912.	3.6	57
161	IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. <i>Nature Communications</i> , 2014, 5, 3303.	12.8	124
162	Caspase Recruitment Domain 6 Protects Against Cardiac Hypertrophy in Response to Pressure Overload. <i>Hypertension</i> , 2014, 64, 94-102.	2.7	30

#	ARTICLE	IF	CITATIONS
163	Autoimmune Basis for Postural Tachycardia Syndrome. <i>Journal of the American Heart Association</i> , 2014, 3, e000755.	3.7	199
164	Interferon Regulatory Factor 7 Protects Against Vascular Smooth Muscle Cell Proliferation and Neointima Formation. <i>Journal of the American Heart Association</i> , 2014, 3, e001309.	3.7	27
165	Interferon regulatory factor 3 protects against adverse neo-intima formation. <i>Cardiovascular Research</i> , 2014, 102, 469-479.	3.8	20
166	Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor $\alpha$ in mice. <i>Journal of Hepatology</i> , 2014, 60, 1046-1054.	3.7	50
167	Suppression of the mTORC1/STAT3/Notch1 pathway by activated AMPK prevents hepatic insulin resistance induced by excess amino acids. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E197-E209.	3.5	63
168	Inducible cardiac arrhythmias caused by enhanced $\beta_1$ -adrenergic autoantibody expression in the rabbit. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H422-H428.	3.2	19
169	AMPK activation prevents excess nutrient-induced hepatic lipid accumulation by inhibiting mTORC1 signaling and endoplasmic reticulum stress response. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1844-1854.	3.8	91
170	Atrial Tachyarrhythmias Induced by the Combined Effects of $\beta_{1/2}$ -adrenergic Autoantibodies and Thyroid Hormone in the Rabbit. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 581-589.	2.4	10
171	Calponin1 inhibits dilated cardiomyopathy development in mice through the $\mu$ PKC pathway. <i>International Journal of Cardiology</i> , 2014, 173, 146-153.	1.7	19
172	Puerarin attenuates pressure overload-induced cardiac hypertrophy. <i>Journal of Cardiology</i> , 2014, 63, 73-81.	1.9	73
173	Interferon Regulatory Factor 1 Is Required for Cardiac Remodeling in Response to Pressure Overload. <i>Hypertension</i> , 2014, 64, 77-86.	2.7	75
174	Never in Mitosis Gene A Related Kinase-6 Attenuates Pressure Overload-Induced Activation of the Protein Kinase B Pathway and Cardiac Hypertrophy. <i>PLoS ONE</i> , 2014, 9, e96095.	2.5	14
175	Atrial tachycardia provoked in the presence of activating autoantibodies to $\beta_2$ -adrenergic receptor in the rabbit. <i>Heart Rhythm</i> , 2013, 10, 436-441.	0.7	20
176	Agonistic Autoantibodies as Vasodilators in Orthostatic Hypotension. <i>Hypertension</i> , 2012, 59, 402-408.	2.7	48
177	Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an "autoimmune" orthostatic hypotension. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 40-47.	2.3	46
178	Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 303, E1234-E1244.	3.5	112
179	Alliin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 1238-1250.	4.2	89
180	Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13818-13823.	7.1	125

#	ARTICLE	IF	CITATIONS
181	Cellular FLICE-Inhibitory Protein Protects Against Cardiac Remodeling Induced by Angiotensin II in Mice. <i>Hypertension</i> , 2010, 56, 1109-1117.	2.7	26